GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures.
Avalon said Tuesday that GSK (NYSE: GSK)... Read more »
Fall is finally arriving, as indicated by the recent shortened work week, and few may object given the unseasonably hot, muggy weather San Diego has been experiencing recently. Track down somewhere... Read more »
An Acadia Pharmaceuticals drug that’s already approved for psychosis associated with Parkinson’s disease could soon be heading to an FDA review to expand the use of the drug to dementia patients.... Read more »
Making beer is a water-intensive process: Along with the water that goes into the product itself, another five to seven gallons of wastewater is produced for every gallon of the... Read more »
Infections caused by the hepatitis B virus, which attacks the liver, are typically treated with drugs that keep the virus from making ever more copies of itself.
However, because those treatments... Read more »
[Corrected 8/27/19, 1:18 p.m. PT. See below.] Remember the simpler times of the mid-2010s, when you could order a latte or cocktail in California without the option of adding CBD?... Read more »
About 15 percent of adults in the US, around 37 million people, are estimated to have chronic kidney disease, according to the Centers for Disease Control. They have very few therapeutic... Read more »
Many facets of the finance industry, a highly regulated sector of the economy, are still reworking the tools used to move around money so that they fit a digital world.
Digital... Read more »
An anti-inflammatory drug that AbbVie has been developing as a successor to adalimumab (Humira), the world’s top-selling drug, won the regulatory OK Friday as a treatment for rheumatoid arthritis (RA).
The... Read more »
TuSimple, an autonomous trucking company, has been conducting test drives for UPS between the Arizona cities of Phoenix and Tucson since May.
Now the corporate venture arm of the global package... Read more »
Wireless giant Qualcomm has appointed Mark McLaughlin, the former CEO of network security company Palo Alto Networks, as chairman of its board of directors.
McLaughlin joined Silicon Valley-based Palo Alto... Read more »
Summer can be a slow time in San Diego, but its startups have stayed busy. Read on for news of recent financings, plus upcoming opportunities to connect with the local tech... Read more »
[Updated 2:33 p.m. Aug. 8. See below.] Organovo says it has run out of money to advance its efforts to develop 3-D “patches” of living human liver tissue to... Read more »
Entrepreneurs who are accepted into the next 20-week accelerator program run by SD Sports Innovators will get the opportunity to learn from senior Qualcomm employees as they work to better their... Read more »
Urinary tract infections are among the most common bacterial infections in the United States, but treatment options are shrinking as resistance to antibiotics commonly prescribed to treat the condition continues to... Read more »
We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look... Read more »
About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21 percent to... Read more »
The first business accelerator program in southeast San Diego is accepting applications for its second cohort of entrepreneurs, who would start the program in fall.
The six-month program, called Connect All... Read more »
HireAHelper.com, an online marketplace that links people who are moving to a new home with local movers and related services, has been acquired by Porch, which operates a marketplace that connects... Read more »
Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies.
The company... Read more »